A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients

Here, Freis's team studied the effectiveness of pentapyrrolidinium (a ganglionic-blocking agent, also called pentolinium) as an antihypertensive treatment. They concluded that the drug had several advantages in the treatment of severe hypertension over another ganglionic-blocking agent, hexamethonium. The drug's attributes, longer duration of action, greater potency, and a more uniform response to oral administration, more than compensated for its side effects and the frequent need to adjust dosage.